TrialDiabetes, obesity & metabolism2021

Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial.

Mark A Espeland et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.